Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Figopitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 17/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Figopitant SCHEMBL21955647 | 1.00 | TACR1 (0.59) | TACR1SCN5ASCN9AOPRM1OPRD1 | |
| SCHEMBL5457820 | 0.88 | TACR1 (0.70) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL3475643 | 0.86 | TACR1 (0.58) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL6836750 | 0.86 | TACR1 (0.58) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL5459971 | 0.84 | TACR1 (0.65) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL3473136 | 0.82 | TACR1 (0.53) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL3473472 | 0.82 | TACR1 (0.53) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL3475829 | 0.82 | TACR1 (0.57) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL7009113 | 0.82 | TACR1 (0.57) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL6836873 | 0.82 | TACR1 (0.57) | TACR1SCN5ASCN9ATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-3643309-B1 | NINTEDANIB FOR USE IN THE TREATMENT OF SYSTEMIC SCLERODERMA | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | disclosed |
| EP-3645120-B1 | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | CHASE THERAPEUTICS CORP (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | disclosed |
| US-12023315-B2 | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | SOMERSET THERAPEUTICS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-11813248-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813247-B2 | NK-1 antagonist compositions and methods for use in treating depression | CHASE THERAPEUTICS CORPORATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-20040048886-A1 | Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6696042-B2 | INHALATION AEROSOL COMPRISING TIOTROPIUM SALT AND PROPELLANT GAS; RESPIRATORY SYSTEM DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-02-24 | — | — | US | disclosed |
| WO-2004004724-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL ANTICHOLINERGIC AGENTS AND NK1-RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | disclosed |
| EP-1370293-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICS AND ON NK1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-13 | — | — | US | disclosed |
| US-6620438-B2 | Arylglycinamide derivatives | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020169181-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002069944-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICS AND ON NK1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | TACR1 85/4885SCN5A 1421/4885SCN9A 2813/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | TACR1 125/4885SCN5A 1657/4885SCN9A 3242/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | TACR1 214/4885SCN5A 1154/4885SCN9A 4072/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | TACR1 62/4885SCN5A 2045/4885SCN9A 4221/4885 |
| US-20040048886-A1 | Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists | CHRM3, CHRNA1, CHRNB1 | TACR1 5/4885SCN5A 398/4885SCN9A 863/4885 |
| US-20020169181-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | TACR2, CHRM3, TACR1 | TACR1 3/4885SCN5A 472/4885SCN9A 1032/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | TACR1 163/4885SCN5A 210/4885SCN9A 492/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | TACR1 125/4885SCN5A 1657/4885SCN9A 3242/4885 |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | TACR2, CHRM3, TACR1 | TACR1 3/4885SCN5A 472/4885SCN9A 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.